Severe fever with thrombocytopenia syndrome (SFTS) is a tick-born hemorrhagic fever caused by a novel *Phlebovirus* of the *Bunyaviridae* family termed the SFTS virus. Since 2009, more than 3500 SFTS cases have been reported in China, Korea, and Japan.[@B1] SFTS varies widely in severity, ranging from inapparent infection to self-limiting febrile illness or death.[@B2] The average fatality rate of SFTS cases in China was reported at 12%, although it reached 30% in some areas.[@B3][@B4] In Korea, the fatality rate is approximately 30%.[@B5] Due to both a high fatality rate and lack of a specific treatment, SFTS has become a major public health threat in endemic areas.

A previous report described successful treatment of two patients with SFTS who progressed rapidly to multiple organ dysfunction (MOD) with plasma exchange (PE) and ribavirin.[@B6] Since then, PE alone or PE combined with ribavirin has occasionally been used to treat rapidly progressing SFTS in some Korean hospitals. In the present study, we collected data on all SFTS cases from these hospitals and compared the clinical outcomes between PE-treated patients (PE group) and non-treated patients (non-PE group).

This retrospective cohort study was conducted at nine Korean hospitals. All consecutive patients aged \>18 years who presented with new-onset fever and had a documented SFTS virus infection between May 2013 and August 2015 were included in the study. SFTS virus infection was confirmed by reverse transcription polymerase chain reaction, which was performed according to a standardized protocol at the Korean Center for Disease Control and Prevention.[@B7] Implementation of therapeutic modalities including PE was determined according to the clinical judgment of the responsible physician(s). PE was performed using fresh-frozen plasma as a plasma substitute: the volume given was determined in accordance with the patient\'s height, weight, and hematocrit level. Data on demographics, comorbidities, clinical features, laboratory findings, severity indices of illness, treatments, and outcomes were collected by reviewing the patients\' medical records. Comorbidities included cardiovascular, pulmonary, hepatobiliary, connective tissue, neuromuscular disorders, malignancy, immunosuppression, and diabetes mellitus. The primary outcome was in-hospital mortality. Secondary outcomes included 30-day survival and the length of intensive care unit (ICU) or hospital stay.

Continuous variables were compared using Student\'s t-test, the Mann-Whitney U-test, or the Kruskal-Wallis test. Categorical variables were compared using Pearson\'s χ^2^ test or Fisher\'s exact test. The Kaplan-Meier method was used to estimate the cumulative probability of survival in SFTS patients, and the log-rank test was employed to compare 30-day survival between treatment groups. To identify risk factors associated with 30-day mortality, univariate and multivariate analyses were performed using a Cox proportional hazards model, and the results are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). IBM SPSS Statistics version 22 (IBM Corporation, Somers, NY, USA) was used for all statistical analyses. Two-tailed *p* values \<0.05 were considered to indicate statistical significance.

A total of 53 patients confirmed as having SFTS virus infection between May 2013 and August 2015 were included: 24 (45.3%) PE cases and 29 (54.7%) non-PE cases ([Table 1](#T1){ref-type="table"}). At the time of initial presentation, chills, fatigue, and myalgia were more common in the non-PE group (all *p*\<0.05), whereas the mean white blood cell count was lower in the PE group (*p*=0.039). There were no significant differences in other baseline characteristics between the two groups. In the PE group, the median interval from symptom onset to implementation of PE was 6 days (range 3--18 days). The median volume of plasma substitute was 2491 mL/session (range 815--8238 mL/session), and the median number of PE sessions was three (range 1--5). The overall in-hospital mortality rate was 32.1% (17/53). Multiple organ failure (8 cases) was the most common cause of death, followed by shock (3 cases), acute coronary syndrome (2 cases), hemorrhage (1 case), and other causes (3 cases). The in-hospital mortality rate did not differ between the PE and non-PE groups \[29.3% vs. 34.5%, relative risk (RR) 0.846, 95% CI 0.380--1.883, *p*=0.680\]. Survival did not differ between the PE and non-PE groups (mean survival time 24.0 days vs. 22.6 days, *p*=0.622 by log-rank test) ([Fig. 1A](#F1){ref-type="fig"}). There were no significance differences in the length of the ICU or hospital stay (*p*=0.281 and 0.680, respectively).

Of the 24 PE cases, 16 (66.7%) were treated with PE within 7 days of symptom onset (early PE group), and eight (33.3%) were treated with PE after 7 days of symptom onset (late PE group). Comparison of the early PE and non-PE groups revealed that the latter was more likely to have one or more comorbidities or fatigue (all *p*\<0.05). There were no significant differences in other baseline characteristics between the early PE and non-PE groups (all *p*\>0.05). The in-hospital mortality of the early PE group did not differ from that of the non-PE group (6.3% vs. 34.5%, RR 0.181, 95% CI 0.026--1.291, *p*=0.067). The early PE group survived longer than the non-PE group (mean survival time 28.4 days vs. 22.6 days, *p*= 0.044 by log-rank test) ([Fig. 1B](#F1){ref-type="fig"}).

In the multivariate model adjusted for several baseline characteristic and PE implementation as a whole, an increased risk of 30-day mortality was associated with older age (adjusted HR 1.104, 95% CI 1.014--1.203, *p*=0.022) and a higher Acute Physiology and Chronic Health Evaluation (APACHE) II score (adjusted HR 1.356, 95% CI 1.071--1.717, *p*=0.011) (model I in [Table 2](#T2){ref-type="table"}). In the multivariate model adjusted for several baseline characteristics and early and late implementation of PE, older age (adjusted HR 1.187, 95% CI 1.045--1.349, *p*=0.009), a higher APACHE II score (adjusted HR 1.600, 95% CI 1.179--2.171, *p*=0.003), early PE implementation (adjusted HR 0.052, 95% CI 0.004--0.678, *p*=0.024), and late PE implementation (adjusted HR 5.513, 95% CI 1.121--27.10, *p*=0.036) were identified as independent risk factors for 30-day mortality (model II in [Table 2](#T2){ref-type="table"}).

The clinical course of SFTS can be divided into three stages: fever (1--7 days after symptom onset), MOD (7--13 days after symptom onset), and convalescence.[@B8] A cytokine-mediated inflammatory response has been shown to play an important role in the pathogenesis of SFTS.[@B9][@B10] In particular, SFTS virus infection triggers a cytokine storm during the early stage of illness, which can cause disease progression to MOD.[@B11] PE can restore homeostasis in patients with sepsis by removing harmful substances (e.g., inflammatory cytokines) and by replacing deficient blood components (e.g., coagulation factors), when fresh-frozen plasma is used as a plasma substitute.[@B12] We hypothesized that PE could modulate the cytokine storm during the early stage of SFTS, preventing progression to MOD and thereby leading to favorable outcomes. This was why PE cases were subdivided into early PE and late PE groups. According to multivariate analyses in the present study, PE implementation (as a whole) was not associated with mortality, whereas early PE implementation was identified as an inverse risk factor for mortality. This finding suggests that PE may play an important role in the early stage of illness, which can maximize its survival benefits in SFTS patients.

Several SFTS cases who were successfully treated with PE have been reported in Korea.[@B13][@B14][@B15] There is no consensus yet on whether PE can improve the clinical outcomes of SFTS patients, in whom PE should be implemented, or when PE should be initiated. The present study aimed to answer these questions. In the present study, PE implementation exerted no favorable effect on in-hospital mortality or 30-day survival rate. In the subgroup analyses, early PE cases showed a longer survival than non-PE cases (*p*=0.044). Because of the small sample size, however, the significant difference in survival time was no longer apparent after correcting for multiple comparisons between subgroups. In addition, the present study was retrospective and non-randomized in nature; thus, it may have been affected by selection bias. The presence of one or more comorbidities was more common in the non-PE group than in the early PE group. In addition, the mean age of the non-PE group was slightly higher than those of the PE and early PE groups, although the difference was not significant. Such minor differences in baseline characteristics between subgroups may have affected the clinical outcomes. Finally, as PE implementation depended entirely on the clinical judgments of the attending physicians, cases with self-limiting SFTS may have been included in the PE or early PE group.

In summary, the results of the present study highlighted an inverse association between early PE implementation and 30-day mortality, which may provide rationale for the early use of PE in SFTS patients. To overcome the limitations of the present study, larger randomized trials with early PE implementation in high-risk SFTS patients for death are needed.
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![Comparison of 30-day survival between treatment groups. (A) PE group vs. non-PE group. There was no significant difference in 30-day survival between the two groups (mean survival time 24.0 days vs. 22.6 days, *p*=0.622 by the log-rank test). (B) Early PE group vs. non-PE group. Survival was longer in the early PE group than in the non-PE group (mean survival time 28.4 days vs. 22.6 days, *p*=0.044 by the log-rank test). PE, plasma exchange.](ymj-58-867-g001){#F1}

###### Baseline Characteristics and Clinical Outcomes between Treatment Groups

![](ymj-58-867-i001)

  Baseline characteristics or clinical outcomes                     No. of cases (%)   *p* value          No. of PE cases (%)   *p* value^\*^                         
  ----------------------------------------------------------------- ------------------ ------------------ --------------------- ------------------ ------------------ -------
  Epidemiology                                                                                                                                                        
   Age (mean±SD, yr)                                                67.4±11.6          62.5±11.6          0.132                 60.9±12.1          65.7±10.6          0.152
   Female sex                                                       13 (44.8)          9 (37.5)           0.590                 7 (43.8)           2 (25.0)           0.588
   Occupational exposure to tick bites                              20 (69.0)          18 (75.0)          0.627                 8 (50.0)           6 (75.0)           0.455
  Comorbidity                                                                                                                                                         
   Cardiovascular disorder                                          9 (31.0)           6 (25.0)           0.627                 1 (6.3)            5 (62.5)           0.014
   Diabetes mellitus                                                6 (20.7)           2 (8.3)            0.269                 1 (6.3)            1 (12.5)           0.422
   Presence of one or more comorbidities                            13 (44.8)          8 (33.3)           0.394                 2 (12.5)           6 (75.0)           0.009
  Clinical features at the time of initial presentation                                                                                                               
   Chills                                                           21 (72.4)          10 (41.7)          0.024                 7 (43.8)           3 (37.5)           0.074
   Fatigue                                                          17 (58.6)          5 (20.8)           0.005                 3 (18.8)           2 (25.0)           0.020
   Headache                                                         9 (31.0)           5 (20.8)           0.402                 4 (25.0)           1 (12.5)           0.568
   Myalgia                                                          14 (48.3)          5 (20.8)           0.038                 5 (31.3)           0                  0.038
   Anorexia, nausea, vomiting                                       18 (62.1)          12 (50.0)          0.378                 7 (43.8)           5 (62.5)           0.463
   Diarrhea                                                         13 (44.8)          11 (45.8)          0.942                 5 (31.3)           6 (75.0)           0.127
   Hypotension (SBP \<90 mm Hg or MAP \<70 mm Hg)                   1 (3.4)            4 (16.7)           0.164                 2 (12.5)           2 (25.0)           0.160
  Laboratory findings at the time of initial presentation                                                                                                             
   White blood cell count (mean±SD, cells/μL)                       2028±890           1562±671           0.039                 1603±752           1478±506           0.178
   Hemoglobin (mean±SD, mg/dL)                                      13.8±1.6           14.1±1.6           0.478                 14.3±1.6           13.7±1.6           0.491
   Platelet count (mean±SD, cells/μL)                               65344±31406        71541±32722        0.486                 75000±34355        64625±30118        0.689
   PT INR \[median (range)\]                                        1.05 (0.93−1.51)   1.12 (0.94−1.49)   0.147                 1.09 (0.95−1.21)   1.15 (0.94−1.49)   0.254
   aPTT \[median (range), sec\]                                     43.7 (28.0−75.8)   46.4 (34.9−65.9)   0.491                 44.5 (34.9−53.0)   49.3 (38.5−65.9)   0.639
   AST level \[median (range), U/L\]                                148 (32−1531)      113 (22−612)       0.313                 91 (22−612)        140 (48−524)       0.388
   LDH level \[median (range), U/L\]                                740 (300−3550)     828 (302−2589)     0.802                 738 (302−1998)     911 (582−2589)     0.675
   CK level \[median (range), U/L\]                                 765 (85−7440)      480 (82−6684)      0.286                 383 (82−6684)      564 (94−3277)      0.564
   Blood urea nitrogen \[median (range), mg/dL\]                    18.7 (3.5−86.0)    14.3 (5.7−48.0)    0.118                 12.8 (5.7−36.3)    19.2 (8.7−48.0)    0.069
   Serum creatinine \[median (range), mg/dL\]                       1.0 (0.6−6.8)      1.1 (0.7−1.4)      0.308                 1.1 (0.8−1.4)      1.1 (0.7−1.2)      0.547
  Severity indices of illness at the time of initial presentation                                                                                                     
   No. of SIRS criteria^†^≥2                                        21 (72.4)          17 (70.8)          0.899                 10 (62.5)          7 (87.5)           0.436
   APACHE II score (mean±SD)                                        10.0±4.2           9.9±4.0            0.942                 9.5±3.7            10.8±4.7           0.889
  Clinical outcomes                                                                                                                                                   
   Length of ICU stay \[median (range), days\]                      4 (0−15)           4.5 (2−11)         0.346                 5 (2−7)            3 (2−10)           0.564
   Length of hospital stay \[median (range), days\]                 7 (0−40)           8 (4−22)           0.281                 9 (4−18)           7.5 (4−22)         0.540
   In-hospital mortality, n (%)                                     10 (34.5)          7 (29.2)           0.680                 1 (6.3)            6 (75.0)           0.003

PE, plasma exchange; SD, standard deviation; SBP, systolic blood pressure; MAP, mean arterial pressure; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; LDH, lactate dehydrogenase; CK, creatinine phosphokinase; SIRS, systemic inflammatory response syndrome; APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.

^\*^Comparison between non-PE, early PE, and late PE groups, ^†^Including 1) heart rate \>90 beats/min, 2) respiratory rate \>24 breaths/min, 3) temperature \>38℃ or \<36℃, or 4) white blood cells \>12000/µL, \<4000/µL, or band formation \>10%.

###### Univariate and Multivariate Analyses of Risk Factors Associated with 30-Day Mortality
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  Variables                                            Univariate model       Multivariate model I^\*^   Multivariate model II^†^                                  
  ---------------------------------------------------- ---------------------- -------------------------- -------------------------- ------- ---------------------- -------
  Age (yr)                                             1.103 (1.037--1.173)   0.002                      1.104 (1.014--1.202)       0.022   1.187 (1.045--1.349)   0.009
  Occupational exposure to tick bites                  2.334 (0.822--6.633)   0.112                      3.125 (0.768--12.71)       0.111   1.523 (0.320--7.246)   0.597
  Presence of one or more comorbidities                3.175 (1.170--8.615)   0.023                      1.688 (0.437--6.518)       0.447   0.388 (0.080--1.886)   0.240
  Hypotension (SBP \<90 mm Hg or MAP \<70 mm Hg)       2.712 (0.780--9.491)   0.116                      0.763 (0.083--6.995)       0.811   0.372 (0.029--4.767)   0.447
  Thrombocytopenia (platelet count \<50000 cells/μL)   1.727 (0.666--4.480)   0.261                      1.784 (0.492--6.467)       0.375   4.561 (0.991--20.99)   0.051
  Coagulopathy (PT INR \>1.5 or aPTT \>60 sec)         1.494 (0.341--6.546)   0.594                      0.678 (0.112--4.106)       0.672   0.159 (0.023--1.096)   0.062
  Azotemia (BUN \>20 mg/dL or serum Cr \>1.5 mg/dL)    2.750 (1.046--7.231)   0.040                      1.060 (0.240--4.672)       0.939   0.456 (0.091--2.284)   0.340
  No. of SIRS criteria^‡^ ≥2                           3.390 (0.775--14.83)   0.105                      0.684 (0.115--4.083)       0.677   1.221 (0.193--7.729)   0.822
  APACHE II score (total point)                        1.264 (1.122--1.424)   \<0.001                    1.356 (1.071--1.717)       0.011   1.600 (1.179--2.171)   0.003
  Plasma exchange                                      0.787 (0.299--2.068)   0.627                      0.973 (0.272--3.476)       0.966   \-                     \-
  Early plasma exchange                                0.155 (0.020--1.209)   0.075                      \-                         \-      0.052 (0.004--0.678)   0.024
  Late plasma exchange                                 2.489 (0.894--6.931)   0.081                      \-                         \-      5.513 (1.121--27.10)   0.036

HR, hazard ratio; CI, confidence interval; SBP, systolic blood pressure; MAP, mean arterial pressure; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time; BUN, blood urea nitrogen; Cr, creatinine; SIRS, systemic inflammatory response syndrome; APACHE, Acute Physiology and Chronic Health Evaluation.

^\*^Multivariate model I was adjusted for age, occupational exposure to tick bites, presence of one or more comorbidities, hypotension, thrombocytopenia, coagulopathy, azotemia, No. of SIRS criteria ≥2, APACHE II score, and PE implementation as a whole, ^†^Multivariate model II was adjusted for age, occupational exposure to tick bites, presence of one or more comorbidities, hypotension, thrombocytopenia, coagulopathy, azotemia, No. of SIRS criteria ≥2, APACHE II score, and early and late PE implementation, ^‡^Including 1) heart rate \>90 beats/min, 2) respiratory rate \>24 breaths/min, 3) temperature \>38℃ or \<36℃, or 4) white blood cells \>12000/µL, \<4000/µL, or band formation \>10%.
